| Linagliptin and Metformin Hydrochloride | Boehringer Ingelheim | ||
| 2.5 mg/ 500,850,1000mg; Tablet, Oral |
Less Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate | |||
|
Yes
| |||
| Jentadueto | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ****** | ******* | **** *** | **** *** | ******* | **** *** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ***** | ******* | **** *** | **** *** | **** *** | **** *** | **** *** | **** *** | ******* | ******* | ******* | ******* | ******* | ******* |
| ****** (*****) | ******* | **** *** | **** *** | **** *** | **** *** | **** *** | **** *** | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** ****** | *** \ ** | *** *, **** | ******* | ******** | ******* *** **** *** *** **** |
| ***** | *** \ ** | *** *, **** | ******* | ********* ******** | ******* *** **** *** *** **** |
| ****** (*****) | *** \ ** | *** *, **** | ******* | ********* ******** | ******* *** **** *** *** **** |
Download ParaIV Report